Provided by Tiger Trade Technology Pte. Ltd.

Annovis Bio, Inc.

2.37
-0.1120-4.52%
Volume:128.22K
Turnover:309.54K
Market Cap:62.76M
PE:-1.64
High:2.47
Open:2.44
Low:2.35
Close:2.48
52wk High:5.50
52wk Low:1.11
Shares:26.50M
Float Shares:23.22M
Volume Ratio:0.96
T/O Rate:0.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4419
EPS(LYR):-2.3061
ROE:-246.14%
ROA:-105.88%
PB:4.77
PE(LYR):-1.03

Loading ...

Annovis Bio: Advancing Phase 3 Neurodegeneration Programs Create Attractive Risk‑Reward Supporting Buy Rating

TIPRANKS
·
Feb 21

Annovis Bio Advances Alzheimer’s Phase 3 Trial After Safety Nod

TIPRANKS
·
Feb 12

Annovis Bio Inc - Dsmb Finds No Safety Concerns, Trial to Continue as Planned

THOMSON REUTERS
·
Feb 12

Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease

GlobeNewswire
·
Feb 12

Annovis Bio Hosts Regulation FD Investor Information Webinar

TIPRANKS
·
Jan 29

Annovis Bio Launches 36-Month Study of Buntanetap in Parkinson's Patients

Reuters
·
Dec 19, 2025

Annovis Bio Inc - to Begin Open-Label Extension Study in January 2026

THOMSON REUTERS
·
Dec 19, 2025

Annovis Bio Inc. Hosts Corporate Update Webinar Featuring CEO Maria Maccecchini

Reuters
·
Dec 16, 2025

Annovis to Host Corporate Update Webinar on January 28, 2026

GlobeNewswire
·
Dec 16, 2025

Annovis Bio Director Michael B. Hoffman Reports Acquisition of Common Shares

Reuters
·
Dec 09, 2025

Annovis Bio to Present Phase 3 Parkinson’s Data at Parkinson Study Group Annual Meeting

Reuters
·
Dec 03, 2025

Director Makes Bold Move with Major Annovis Bio Stock Purchase

TIPRANKS
·
Nov 26, 2025

Annovis Bio Director Michael B. Hoffman Reports Acquisition of Common Shares

Reuters
·
Nov 26, 2025

Annovis Bio Unveils New Clinical Data on Buntanetap at CTAD 2025

Reuters
·
Nov 24, 2025

Annovis Bio Inc. Director Michael B. Hoffman Reports Acquisition of Common Shares

Reuters
·
Nov 22, 2025

Annovis Bio Receives Buy Rating Amid Promising Phase 3 Trial Results and Strategic FDA Discussions for Buntanetap

TIPRANKS
·
Nov 20, 2025

Director Makes Bold Move with Major Annovis Bio Stock Purchase

TIPRANKS
·
Nov 19, 2025

Annovis announces FDA meeting to discuss PDD program

TIPRANKS
·
Nov 18, 2025

BRIEF-Annovis Announces FDA Meeting To Discuss Parkinson's Disease Dementia Program Reaffirms FDA Alignment On Pivotal Phase 3 Alzheimer's Disease Study

Reuters
·
Nov 18, 2025

Annovis Bio Inc - Announces FDA Type C Meeting for January 2026

THOMSON REUTERS
·
Nov 18, 2025